ZELINKA, Jiří, Jiří BLAHÁK, Vojtěch PEŘINA, Rita PACASOVÁ, Jana TREGLEROVÁ and Oliver BULIK. The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study. Biomedical Papers. Univerzita Palackého v Olomouci, 2021, vol. 165, No 3, p. 322-327. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2020.023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study
Authors ZELINKA, Jiří, Jiří BLAHÁK, Vojtěch PEŘINA, Rita PACASOVÁ, Jana TREGLEROVÁ and Oliver BULIK.
Edition Biomedical Papers, Univerzita Palackého v Olomouci, 2021, 1213-8118.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.648
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.5507/bp.2020.023
UT WoS 000715922000013
Keywords in English medication related osteonecrosis of the jawplatelet rich fibrinsurgical treatment
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/4/2023 08:37.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed bone in the maxillofacial region persisting for more than eight weeks in patients who are or were treated with antiresorptive or antiangiogenic agents and had no radiation therapy to the craniofacial region or obvious metastatic disease of the jaws. It is a recognised side effect of antiresorptive or antiangiogenic medication. To date, there is no specific gold standard treatment for MRONJ cases. The aim of this study was to evaluate the successful rate of surgical treatment with adjuvant local application of platelet rich fibrin.
PrintDisplayed: 23/7/2024 01:21